Ovarian cancer Rx
March 16, 2016
A NEW oral therapy, for women
living with BRCA-mutated high grade
serous ovarian cancer
(HGSOC) has been registered by the
Therapeutic Goods Administration.
AstraZeneca has announced that
its Lynparza (olaparib) will be made
available to eligible women under a
co-payment scheme.
Patients will be required to pay
for one month of Lynparza at
months 3 and 6 - $6,180 each time
totalling $13,620.
All other months of Lynparza will
be provided to patients at no cost
(months 1, 2, 4, 5, and 7 onwards),
but where a dispensing fee applies,
that will not be covered in the
AstraZeneca scheme.
New enrolments to the assisted
patient access program are
available now and will close “on or
around 31 Dec 2016”, the company
said, adding that all patients will
continue to receive the drug as long
as deemed medically beneficial or
the drug is made available through
the Pharmaceutical Benefits
Scheme.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Mar 16